



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

NUCC-0226272

| | | | |
|--------------------|---|-------|----------|
| Cat. No.: | HY-157844 | | |
| CAS No.: | 3004503-12-9 | | |
| Molecular Formula: | C ₆₇ H ₉₁ N ₉ O ₈ S | | |
| Molecular Weight: | 1182.56 | | |
| Target: | PROTACs; Histone Methyltransferase | | |
| Pathway: | PROTAC; Epigenetics | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 140 mg/mL (118.39 mM)
 * "≥" means soluble, but saturation unknown.

| Preparing Stock Solutions | Solvent | | Mass | | |
|---------------------------|---------------|--|-----------|-----------|-----------|
| | Concentration | | 1 mg | 5 mg | 10 mg |
| | 1 mM | | 0.8456 mL | 4.2281 mL | 8.4562 mL |
| | 5 mM | | 0.1691 mL | 0.8456 mL | 1.6912 mL |
| | 10 mM | | 0.0846 mL | 0.4228 mL | 0.8456 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

NUCC-0226272 is a potent PROTAC that targets EZH2 for degradation. NUCC-0226272 has anti-proliferative effect. NUCC-0226272 has the potential for cancer research^[1].

IC₅₀ & Target

EZH2

In Vitro

NUCC-0226272 (0.01-10 μM; 5 days) shows anti-proliferative effect in LNCaP and 22Rv1 cells^[1].
 NUCC-0226272 (10 μM; 6 days) shows strong degradation of EZH2, as well as reduction of PRC2 component SUZ12, and reduced H3K27me3 levels in C4-2B cells^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pharmacokinetic Parameters of NUCC-0226272 in C57Bl/6 mouse^[1].

IP (4 mg/kg)

| | |
|---------------------------------|----------|
| T_{\max} (h) | 0.83 |
| C_{\max} (ng/mL) | 3650 |
| AUC_{last} (min·ng/mL) | 12777389 |
| $t_{1/2}$ (h) | 3.46 |
| CL (mL/min/kg) | 3.11 |
| V_{ss} (L/kg) | 3.11 |

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Gary E. Schiltz, et al. Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (ezh2) and proteolysis-targeting chimeric derivatives thereof (protacs) that induce degradation of ezh2. US20230346953A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA